Corvus Pharmaceuticals, Inc. (CRVS) Financials

NASDAQ Currency in USD Disclaimer

$4.90

north_east $0.35 (7.69%)
Day's range
$4.55
Day's range
$4.94

CRVS Income statement / Annual

Last year (2023), Corvus Pharmaceuticals, Inc.'s total revenue was $0.00, and the percentage change from the previous year is not available. In 2023, Corvus Pharmaceuticals, Inc.'s net income was -$27.03 M. See Corvus Pharmaceuticals, Inc.�s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost of Revenue $151,000.00 $367,000.00 $460,000.00 $632,000.00 $743,000.00 $847,000.00 $842,000.00 $594,000.00 $148,000.00 $0.00
Gross Profit -$151,000.00 -$367,000.00 -$460,000.00 -$632,000.00 -$743,000.00 -$847,000.00 -$842,000.00 -$594,000.00 -$148,000.00 $0.00
Gross Profit Ratio 0 0 0 0 0 0 0 0 0 0
Research and Development Expenses $16.53 M $24.47 M $29.12 M $31.83 M $37.98 M $38.59 M $46.31 M $29.36 M $11.35 M $41,455.00
General & Administrative Expenses $6.88 M $8.10 M $9.52 M $11.93 M $10.88 M $10.64 M $10.22 M $7.62 M $2.42 M $134,182.00
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $6.88 M $8.10 M $9.52 M $11.93 M $10.88 M $10.64 M $10.22 M $7.62 M $2.42 M $134,182.00
Other Expenses $0.00 $587,000.00 $235,000.00 $37.46 M $0.00 $0.00 $0.00 $0.00 -$17.60 M $0.00
Operating Expenses $23.41 M $32.57 M $38.63 M $43.76 M $48.85 M $49.22 M $56.52 M $36.98 M $13.77 M $175,636.00
Cost And Expenses $23.41 M $32.57 M $38.63 M $43.76 M $48.85 M $49.22 M $56.52 M $36.98 M $13.77 M $175,636.00
Interest Income $0.00 $654.00 $0.00 $540,000.00 $2.18 M $2.28 M $861,000.00 $601,000.00 $35,000.00 $0.00
Interest Expense $1.58 M $654,000.00 $15,000.00 $540,000.00 $2.18 M $2.28 M $0.00 $601,000.00 $0.00 $0.00
Depreciation & Amortization $151,000.00 $367,000.00 $460,000.00 $632,000.00 $743,000.00 $847,000.00 $842,000.00 $594,000.00 $148,000.00 $175,636.00
EBITDA -$26.88 M -$40.94 M -$42.78 M -$5.36 M -$48.85 M -$46.09 M -$54.82 M -$35.78 M -$31.19 M $14,636.00
EBITDA Ratio 0 0 0 0 0 0 0 0 0 0
Operating Income Ratio 0 0 0 0 0 0 0 0 0 0
Total Other Income/Expenses Net -$3.62 M -$8.74 M -$4.61 M $37.77 M $2.18 M $2.28 M $861,000.00 $601,000.00 -$17.57 M $0.00
Income Before Tax -$27.03 M -$41.31 M -$43.24 M -$6.00 M -$46.67 M -$46.94 M -$55.66 M -$36.38 M -$31.34 M -$175,636.00
Income Before Tax Ratio 0 0 0 0 0 0 0 0 0 0
Income Tax Expense $0.00 $8.74 M -$5.04 M -$1.17 M -$2.93 M $2.28 M -$842,000.00 -$594,000.00 -$35,000.00 $0.00
Net Income -$27.03 M -$50.05 M -$38.20 M -$4.82 M -$43.75 M -$46.94 M -$55.66 M -$36.38 M -$31.34 M -$175,636.00
Net Income Ratio 0 0 0 0 0 0 0 0 0 0
EPS -0.56 -1.08 -0.91 -0.16 -1.49 -1.71 -2.72 -2.36 -1.54 -1.03
EPS Diluted -0.56 -1.08 -0.91 -0.16 -1.49 -1.71 -2.72 -2.36 -1.54 -1.03
Weighted Average Shares Out $48.03 M $46.55 M $41.85 M $29.48 M $29.35 M $27.51 M $20.49 M $15.42 M $20.41 M $170,000.00
Weighted Average Shares Out Diluted $48.03 M $46.55 M $41.85 M $29.48 M $29.35 M $27.51 M $20.49 M $15.42 M $20.41 M $170,278.00
Link